Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.

TitleElevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.
Publication TypeJournal Article
Year of Publication2004
AuthorsKumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, Conzelmann E, Sanda MG, Wei JT, Rubin MA, Chinnaiyan AM
JournalAm J Pathol
Date Published2004 Mar
KeywordsBiopsy, Needle, Humans, Immunoblotting, Immunohistochemistry, Male, Microdissection, Prostatic Neoplasms, Racemases and Epimerases, Reverse Transcriptase Polymerase Chain Reaction, RNA, Messenger, Tumor Markers, Biological

Alpha-methylacyl-CoA racemase (AMACR) is a peroxisomal and mitochondrial enzyme involved in the beta-oxidation of branched fatty acids, shown to be elevated in prostate cancer by several recent studies. Sequence variants of AMACR have been linked to prostate cancer risk. Although mRNA transcript, protein, and sequence variants of AMACR have been studied in the context of prostate cancer, AMACR enzymatic activity has not been addressed. Here we present evidence that AMACR activity is consistently elevated in prostate cancer tissue specimens. This activity can be immunodepleted from prostate cancer tissue extracts. Furthermore, mock needle biopsy cores containing foci of prostate cancer exhibited increased AMACR enzymatic activity, correlating with both protein levels and histopathology. Taken together, our studies suggest that AMACR activity is increased in prostate cancer relative to benign epithelia and suggests that monitoring AMACR activity levels in prostate needle biopsies may have clinical applications.

Alternate JournalAm. J. Pathol.
PubMed ID14982833
PubMed Central IDPMC1613269
Grant ListP50CA69568 / CA / NCI NIH HHS / United States
R01 CA8241901-A1 / CA / NCI NIH HHS / United States
R01AG21404 / AG / NIA NIH HHS / United States